miR-337-5p promotes the development of cardiac hypertrophy by targeting Ubiquilin-1 (UBQLN1)

References

• Gogiraju R, Bochenek ML, Schafer K. Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure. Front Cardiovasc Med. 2019;6:20.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. NAT REV CARDIOL. 2018;15:387–407.
   PubMed Web of Science ®Google Scholar
• Zhu L, Li C, Liu Q, et al. Molecular biomarkers in cardiac hypertrophy. J CELL MOL MED. 2019;23(3):1671–1677.
   PubMed Web of Science ®Google Scholar
• Liao HH, Jia XH, Liu HJ, et al. The role of PPARs in pathological cardiac hypertrophy and heart failure. Curr Pharm Des. 2017;23(11):1677–1686.
   PubMed Web of Science ®Google Scholar
• Samak M, Fatullayev J, Sabashnikov A, et al. Cardiac hypertrophy: an introduction to molecular and cellular basis. Med Sci Monit Basic Res. 2016;22:75–79.
   PubMed Web of Science ®Google Scholar
• Bartel DP. Metazoan microRNAs. Cell. 2018;173:20–51.
   PubMed Web of Science ®Google Scholar
• Li Z, Xu C, Sun D. MicroRNA-488 serves as a diagnostic marker for atherosclerosis and regulates the biological behavior of vascular smooth muscle cells. Bioengineered. 2021;12(1):4092–4099.
   PubMed Web of Science ®Google Scholar
• Ooi JY, Bernardo BC, McMullen JR. The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy. FUTURE MED CHEM. 2014;6(2):205–222.
   PubMed Web of Science ®Google Scholar
• Yang Y, Del RD, Nakano N, et al. miR-206 mediates YAP-Induced cardiac hypertrophy and survival. CIRC RES. 2015;117(10):891–904.
   PubMed Web of Science ®Google Scholar
• Kuwabara Y, Horie T, Baba O, et al. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. CIRC RES. 2015;116(2):279–288.
   PubMed Web of Science ®Google Scholar
• Indolfi C, Curcio A. Stargazing microRNA maps a new miR-21 star for cardiac hypertrophy. J CLIN INVEST. 2014;124(5):1896–1898.
   PubMed Web of Science ®Google Scholar
• Seok HY, Chen J, Kataoka M, et al. Loss of microRNA-155 protects the heart from pathological cardiac hypertrophy. CIRC RES. 2014;114(10):1585–1595.
   PubMed Web of Science ®Google Scholar
• Huang ZP, Chen J, Seok HY, et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. CIRC RES. 2013;112(9):1234–1243.
   PubMed Web of Science ®Google Scholar
• Yang S, Guo J, Zhou L, et al. miR-148b-3p, miR-337-5p and miR-423-5p expression in alveolar ridge atrophy and their roles in the proliferation and apoptosis of OMMSCs. EXP THER MED. 2018;16:5334–5342.
   PubMed Web of Science ®Google Scholar
• Wang X, Suofu Y, Akpinar B, et al. Systemic antimiR-337-3p delivery inhibits cerebral ischemia-mediated injury. NEUROBIOL DIS. 2017;105:156–163.
   PubMed Web of Science ®Google Scholar
• Liu HL, Zhu JG, Liu YQ, et al. Identification of the microRNA expression profile in the regenerative neonatal mouse heart by deep sequencing. CELL BIOCHEM BIOPHYS. 2014;70(1):635–642.
   PubMed Web of Science ®Google Scholar
• Zhang C, Saunders AJ. An emerging role for Ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov Med. 2009;8:18–22.
   PubMedGoogle Scholar
• Lindsey ML, Kassiri Z, Virag JAI, et al. Guidelines for measuring cardiac physiology in mice. Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H733–H752.
   PubMed Web of Science ®Google Scholar
• Nie X, Fan J, Li H, et al. miR-217 promotes cardiac hypertrophy and dysfunction by targeting PTEN. Mol Ther Nucleic Acids. 2018;7:254–266.
   Google Scholar
• Xu Y, Luo Y, Liang C, et al. LncRNA-mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p/KLF4/myocardin axis. J Mol Cell Cardiol. 2020;139:47–61.
   PubMed Web of Science ®Google Scholar
• Liang Z, Xu J, Ma Z, et al. MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9. Bioengineered. 2020;11(1):70–80.
   PubMed Web of Science ®Google Scholar
• Zuo XL, Chen ZQ, Wang JF, et al. miR-337-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells through targeting JAK2. AM J CANCER RES. 2018;8:662–674.
   PubMed Web of Science ®Google Scholar
• Cui H, Song R, Wu J, et al. MicroRNA-337 regulates the PI3K/AKT and Wnt/beta-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2. AM J CANCER RES. 2018;8:405–421.
   PubMed Web of Science ®Google Scholar
• Zheng L, Jiao W, Mei H, et al. miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14. Oncotarget. 2016;7(26):40314–40328.
   PubMedGoogle Scholar
• Kang W, Huang T, Zhou Y, et al. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. CELL DEATH DIS. 2018;9(2):92.
   PubMed Web of Science ®Google Scholar
• Zhang ZW, Men T, Feng RC, et al. miR-375 inhibits proliferation of mouse pancreatic progenitor cells by targeting YAP1. CELL PHYSIOL BIOCHEM. 2013;32(6):1808–1817.
   PubMedGoogle Scholar
• Wang Y, Lieberman R, Pan J, et al. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. MOL CANCER. 2016;15(1):70.
   PubMedGoogle Scholar
• Lassalle S, Zangari J, Popa A, et al. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. Oncotarget. 2016;7(21):30461–30478.
   PubMedGoogle Scholar
• Hong S, Noh H, Teng Y, et al. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. NEOPLASIA. 2014;16(4):279–290.
   PubMed Web of Science ®Google Scholar
• Jung HM, Phillips BL, Chan EK. miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3zeta. MOL CANCER. 2014;13(1):80.
   PubMed Web of Science ®Google Scholar
• Kleijnen MF, Shih AH, Zhou P, et al. The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. MOL CELL. 2000;6(2):409–419.
   PubMed Web of Science ®Google Scholar
• Rothenberg C, Srinivasan D, Mah L, et al. Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. HUM MOL GENET. 2010;19(16):3219–3232.
   PubMed Web of Science ®Google Scholar
• Mueller TD, Kamionka M, Feigon J. Specificity of the interaction between ubiquitin-associated domains and ubiquitin. J BIOL CHEM. 2004;279(12):11926–11936.
   PubMed Web of Science ®Google Scholar
• Shah PP, Lockwood WW, Saurabh K, et al. Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells. ONCOGENE. 2015;34(13):1709–1717.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Z, Gu J, et al. Plic-1, a new target in repressing epileptic seizure by regulation of GABAAR function in patients and a rat model of epilepsy. Clin Sci (Lond). 2015;129(12):1207–1223.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ackerman SL. Endoplasmic reticulum stress in health and disease. CURR OPIN CELL BIOL. 2006;18(4):444–452.
   PubMed Web of Science ®Google Scholar
• Lee DY, Arnott D, Brown EJ. Ubiquilin4 is an adaptor protein that recruits Ubiquilin1 to the autophagy machinery. EMBO REP. 2013;14(4):373–381.
   PubMed Web of Science ®Google Scholar
• N’Diaye EN, Kajihara KK, Hsieh I, et al. PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. EMBO REP. 2009;10(2):173–179.
   PubMed Web of Science ®Google Scholar
• Lu A, Hiltunen M, Romano DM, et al. Effects of ubiquilin 1 on the unfolded proteiresponse. J MOL NEUROSCI. 2009;38(1):19–30.
   PubMed Web of Science ®Google Scholar
• Lim PJ, Danner R, Liang J, et al. Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. J CELL BIOL. 2009;187(2):201–217.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu L, Hettinger CL, et al. Ubiquilin-1 protects cells from oxidative stress and ischemic stroke caused tissue injury in mice. J NEUROSCI. 2014;34(8):2813–2821.
   PubMed Web of Science ®Google Scholar
• Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. CIRC RES. 1995;77(6):1040–1052.
   PubMed Web of Science ®Google Scholar
• Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. CIRCULATION. 2003;107(12):1664–1670.
   PubMed Web of Science ®Google Scholar
• Wang J, Lv P. Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells. Bioengineered. 2021;12(1):755–762.
   PubMed Web of Science ®Google Scholar
• Sciarretta S, Volpe M, Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. CIRC RES. 2014;114(3):549–564.
   PubMed Web of Science ®Google Scholar
• Wu S, Mikhailov A, Kallo-Hosein H, et al. Characterization of ubiquilin 1, an mTOR-interacting protein. Biochim Biophys Acta. 2002;1542(1–3):41–56.
   PubMed Web of Science ®Google Scholar
• Zhanga C, Aleister J. Saunders. An emerging role for Ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov Med. 2019;8:18–22.
   Google Scholar